New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer
Xiaoxiao Jiang Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS
Search for more papers by this authorHui Qian MS
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS
Search for more papers by this authorCorresponding Author
Wen-Xing Ding Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS
ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Wen-Xing Ding, Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center
MS 1018, 3901 Rainbow Blvd.
Kansas City, KS 66160
E-mail: [email protected]
Tel.: +1-913-588-9813
Search for more papers by this authorXiaoxiao Jiang Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS
Search for more papers by this authorHui Qian MS
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS
Search for more papers by this authorCorresponding Author
Wen-Xing Ding Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS
ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Wen-Xing Ding, Ph.D.
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center
MS 1018, 3901 Rainbow Blvd.
Kansas City, KS 66160
E-mail: [email protected]
Tel.: +1-913-588-9813
Search for more papers by this author
References
- 1Mahdessian H, Taxiarchis A, Popov S, Silveira A, Franco-Cereceda A, Hamsten A, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A 2014; 111: 8913-8918.
- 2Holmen OL, Zhang HE, Fan Y, Hovelson DH, Schmidt EM, Zhou W, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46: 345-351.
- 3Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-356.
- 4Smagris E, Gilyard S, BasuRay S, Cohen JC, Hobbs HH. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 2016; 291: 10659-10676.
- 5Fan Y, Lu H, Guo Y, Zhu T, Garcia-Barrio MT, Jiang Z, et al. Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology 2016; 150: 1208-1218.
- 6Ehrhardt N, Doche ME, Chen S, Mao HZ, Walsh MT, Bedoya C, et al. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis. Hum Mol Genet 2017; 26: 2719-2731.
- 7Newberry EP, Hall Z, Xie Y, Molitor EA, Bayguinov PO, Strout GW, et al. Liver specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis and hepatocellular cancer. Hepatology 2021; 74: 1203–1219.
- 8Borén J, Adiels M, Björnson E, Matikainen N, Söderlund S, Rämö J, et al. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight 2020; 5:e144079.
- 9Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol 2021; 74: 775-782.
- 10Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506-514.
Author names in bold designate shared co-first authorship.
